Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julio C Chavez

Showing results (91-100 of 132) with videos related to

Pageof 14
Sort By:
Transplantation and Cellular Therapy|April 4, 2022
Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell TherapyAasha I Hoogland, Anna Barata, Jennifer Logue, et al.
Leukemia & Lymphoma|October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of originTalha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene CiloleucelRawan Faramand, Michael Jain, Verena Staedtke, et al.
Transplantation and Cellular Therapy|September 29, 2022
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including DialysisAnthony C Wood, Ariel Perez Perez, Brian Arciola, et al.
Haematologica|April 25, 2020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphomaJennifer M Logue, Elisa Zucchetti, Christina A Bachmeier, et al.
British Journal of Haematology|May 21, 2020
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapyNicole A Carreau, Philippe Armand, Reid W Merryman, et al.
The Journal of Clinical Investigation|September 28, 2018
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomasYuan Ren, Chengfeng Bi, Xiaohong Zhao, et al.
Cancer Medicine|February 28, 2021
Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucelAasha I Hoogland, Reena V Jayani, Aaron Collier, et al.
Blood|October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 12, 2017
Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative StudyMohamed A Kharfan-Dabaja, Renju Raj, Liana Nikolaenko, et al.
Pageof 14

Showing results (91-100 of 132) with videos related to

Sort By:
Pageof 14
Transplantation and Cellular Therapy|April 4, 2022
Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell TherapyAasha I Hoogland, Anna Barata, Jennifer Logue, et al.
Leukemia & Lymphoma|October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of originTalha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene CiloleucelRawan Faramand, Michael Jain, Verena Staedtke, et al.
Transplantation and Cellular Therapy|September 29, 2022
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including DialysisAnthony C Wood, Ariel Perez Perez, Brian Arciola, et al.
Haematologica|April 25, 2020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphomaJennifer M Logue, Elisa Zucchetti, Christina A Bachmeier, et al.
British Journal of Haematology|May 21, 2020
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapyNicole A Carreau, Philippe Armand, Reid W Merryman, et al.
The Journal of Clinical Investigation|September 28, 2018
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomasYuan Ren, Chengfeng Bi, Xiaohong Zhao, et al.
Cancer Medicine|February 28, 2021
Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucelAasha I Hoogland, Reena V Jayani, Aaron Collier, et al.
Blood|October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 12, 2017
Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative StudyMohamed A Kharfan-Dabaja, Renju Raj, Liana Nikolaenko, et al.
Pageof 14